BMS’ Anemia Drug Reblozyl Flunks Phase III Myelofibrosis Trial
Despite the failure, BMS remains “encouraged” by Reblozyl’s clinical activity in myelofibrosis-associated anemia and will approach regulators to discuss potential submissions for this indication, for which few treatment options exist.
BMS’ Anemia Drug Reblozyl Flunks Phase III Myelofibrosis Trial Read More »
